Trials / Completed
CompletedNCT00453271
Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail
A Randomized, Double-Blind, Parallel-Group,Multicenter, Dose-Response, Vehicle-Controlled Study of the Safety and Efficacy of NB-002 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 443 (actual)
- Sponsor
- NanoBio Corporation · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to determine whether NB002, 0.25%, and 0.5% are safe and effective in the treatment of distal subungual onychomycosis of the toenail.
Detailed description
The purpose of the study is to determine whether NB002, 0.25%, and 0.5% are safe and effective in the treatment of distal subungual onychomycosis of the toenail.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NB-002 | |
| DRUG | Vehicle control |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2007-03-28
- Last updated
- 2013-05-23
Locations
24 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00453271. Inclusion in this directory is not an endorsement.